CN112741835A - 用于运动机能亢进性运动障碍的治疗的vmat2抑制剂 - Google Patents

用于运动机能亢进性运动障碍的治疗的vmat2抑制剂 Download PDF

Info

Publication number
CN112741835A
CN112741835A CN202011483135.XA CN202011483135A CN112741835A CN 112741835 A CN112741835 A CN 112741835A CN 202011483135 A CN202011483135 A CN 202011483135A CN 112741835 A CN112741835 A CN 112741835A
Authority
CN
China
Prior art keywords
htbz
hexahydro
dimethoxy
pyrido
plasma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202011483135.XA
Other languages
English (en)
Chinese (zh)
Inventor
克里斯托弗·F·奥布赖恩
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Neurocrine Biosciences Inc
Original Assignee
Neurocrine Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurocrine Biosciences Inc filed Critical Neurocrine Biosciences Inc
Publication of CN112741835A publication Critical patent/CN112741835A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychology (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
CN202011483135.XA 2014-05-06 2015-05-06 用于运动机能亢进性运动障碍的治疗的vmat2抑制剂 Pending CN112741835A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461989240P 2014-05-06 2014-05-06
US61/989,240 2014-05-06
CN201580023821.XA CN106456629A (zh) 2014-05-06 2015-05-06 用于运动机能亢进性运动障碍的治疗的vmat2抑制剂

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201580023821.XA Division CN106456629A (zh) 2014-05-06 2015-05-06 用于运动机能亢进性运动障碍的治疗的vmat2抑制剂

Publications (1)

Publication Number Publication Date
CN112741835A true CN112741835A (zh) 2021-05-04

Family

ID=53264772

Family Applications (3)

Application Number Title Priority Date Filing Date
CN202011483135.XA Pending CN112741835A (zh) 2014-05-06 2015-05-06 用于运动机能亢进性运动障碍的治疗的vmat2抑制剂
CN202011483141.5A Pending CN112741836A (zh) 2014-05-06 2015-05-06 用于运动机能亢进性运动障碍的治疗的vmat2抑制剂
CN201580023821.XA Pending CN106456629A (zh) 2014-05-06 2015-05-06 用于运动机能亢进性运动障碍的治疗的vmat2抑制剂

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN202011483141.5A Pending CN112741836A (zh) 2014-05-06 2015-05-06 用于运动机能亢进性运动障碍的治疗的vmat2抑制剂
CN201580023821.XA Pending CN106456629A (zh) 2014-05-06 2015-05-06 用于运动机能亢进性运动障碍的治疗的vmat2抑制剂

Country Status (24)

Country Link
US (3) US20170071932A1 (enExample)
EP (3) EP3936130B1 (enExample)
JP (4) JP6635945B2 (enExample)
KR (5) KR20240011255A (enExample)
CN (3) CN112741835A (enExample)
AU (1) AU2015256012B2 (enExample)
CA (1) CA2947736C (enExample)
CY (1) CY1125058T1 (enExample)
DK (2) DK3139925T3 (enExample)
ES (2) ES2904526T3 (enExample)
FI (1) FI3936130T3 (enExample)
HR (2) HRP20240459T1 (enExample)
HU (2) HUE057839T2 (enExample)
IL (1) IL248745B (enExample)
LT (2) LT3936130T (enExample)
MX (1) MX387625B (enExample)
NZ (1) NZ725826A (enExample)
PL (2) PL3139925T3 (enExample)
PT (2) PT3936130T (enExample)
RS (2) RS65359B1 (enExample)
RU (1) RU2753740C2 (enExample)
SI (2) SI3139925T1 (enExample)
SM (2) SMT202200193T1 (enExample)
WO (1) WO2015171802A1 (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115304596A (zh) * 2015-10-30 2022-11-08 纽罗克里生物科学有限公司 Valbenazine盐及其多晶形物
SI3394057T1 (sl) 2015-12-23 2022-06-30 Neurocrine Biosciences, Inc. Sintetičen postopek za pripravo (S)-(2R,3R,11bR)-3-izobutil-9,10-dimetoksi-2,3,4,6,7,11b-heksahidro-1H- pirido(2,1,-a)izokinolin-2-il 2-amino-3-metilbutanoat di(4-metilbenzensulfonata)
US10442800B2 (en) 2016-06-29 2019-10-15 Crystal Pharmaceutical (Suzhou) Co., Ltd. Crystal forms of NBI-98854, preparation method and use thereof
WO2018102673A1 (en) * 2016-12-02 2018-06-07 Neurocrine Biosciences, Inc. Use of valbenazine for treating schizophrenia or schizoaffective disorder
WO2018130345A1 (en) 2017-01-10 2018-07-19 Sandoz Ag Crystalline valbenazine free base
MY199695A (en) 2017-01-27 2023-11-18 Neurocrine Biosciences Inc Methods for the administration of certain vmat2 inhibitors
WO2018153632A1 (en) 2017-02-27 2018-08-30 Sandoz Ag Crystalline forms of valbenazine salts
WO2018164996A1 (en) * 2017-03-06 2018-09-13 Neurocrine Biosciences, Inc. Dosing regimen for valbenazine
GB201705305D0 (en) * 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
CN110691596A (zh) * 2017-04-01 2020-01-14 阿德普蒂奥制药有限公司 药物组合物
US20190111035A1 (en) * 2017-04-01 2019-04-18 Adeptio Pharmaceuticals Limited Pharmaceutical compositions
GB201705306D0 (en) 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
GB201705302D0 (en) 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
CA3057543A1 (en) * 2017-04-01 2018-10-04 Adeptio Pharmaceuticals Limited (+)-alpha-dihydrotetrabenazine for use in the treatment a movement disorder
GB201705304D0 (en) 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
GB201705303D0 (en) 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
WO2018200605A1 (en) * 2017-04-26 2018-11-01 Neurocrine Biosciences, Inc. Use of valbenazine for treating levodopa-induced dyskinesia
DK3684333T3 (da) 2017-09-21 2025-05-12 Neurocrine Biosciences Inc Valbenazin-formulering med høj dosis og sammensætninger, fremgangsmåder og kits relateret hertil
US20200230127A1 (en) 2017-10-10 2020-07-23 Neurocrine Biosciences, Inc. Methods for the Administration of Certain VMAT2 Inhibitors
KR20250070134A (ko) 2017-10-10 2025-05-20 뉴로크린 바이오사이언시즈 인코퍼레이티드 특정 vmat2 억제제의 투여 방법
RU2020114598A (ru) 2017-11-08 2021-12-09 Фореси Фармасьютикалс Ко., Лтд. Сложные эфиры дигидротетрабеназина
JP7212958B2 (ja) 2017-12-26 2023-01-26 ▲蘇▼州科睿思制▲葯▼有限公司 バルベナジントシル酸塩の結晶形及びその製造方法並びに用途
AU2019261403B2 (en) 2018-04-25 2025-05-15 Shinkei Therapeutics, Inc. Tetrabenazine transdermal delivery device
GB201808464D0 (en) 2018-05-23 2018-07-11 Adeptio Pharmaceuticals Ltd Pharmaceutical compounds for use in treating huntington's disease
MX2020013004A (es) 2018-06-14 2021-02-17 Neurocrine Biosciences Inc Compuestos inhibidores del transportador de monoamina 2 (vmat2), composiciones, y metodos relacionados con los mismos.
BR112021000019A2 (pt) 2018-08-15 2021-04-06 Neurocrine Biosciences Inc. Métodos para administração de certos inibidores de vmat2
EP3860599B1 (en) 2018-10-04 2024-05-15 Adeptio Pharmaceuticals Limited (+)-alpha-dihydrotetrabenazine dosage regimen for treating movement disorders
IL321020A (en) * 2019-05-09 2025-07-01 Neurocrine Biosciences Inc Methods of administering certain vmat2 inhibitors
US10940141B1 (en) 2019-08-23 2021-03-09 Neurocrine Biosciences, Inc. Methods for the administration of certain VMAT2 inhibitors

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2081929B1 (en) * 2006-11-08 2013-01-09 Neurocrine Biosciences, Inc. Substituted 3-isobutyl-9, 10-dimethoxy-1,3,4,6,7,11b-hexahydro-2h-pyrido[2,1-a]isoquinolin-2-ol compounds and methods relating thereto
EP2083744A4 (en) * 2006-11-09 2013-08-28 Univ New York DEGRADED GLASS / ZIRCONIUM / GLASS STRUCTURES FOR DAMAGE-RESISTANT DENTAL AND ORTHOPEDIC CERAMIC PROSTHESES
WO2011019956A2 (en) * 2009-08-12 2011-02-17 Biovail Laboratories International (Barbados) S.R.L. Pharmaceutical compositions
US20110053866A1 (en) * 2008-08-12 2011-03-03 Biovail Laboratories International (Barbados) S.R.L. Pharmaceutical compositions
GB2462611A (en) 2008-08-12 2010-02-17 Cambridge Lab Pharmaceutical composition comprising tetrabenazine
EP3345905B1 (en) 2008-09-18 2021-09-01 Auspex Pharmaceuticals, Inc. Deuterated benzoquinolizine derivatives as inhibitors of vesicular monoamine transporter 2
WO2011153157A2 (en) * 2010-06-01 2011-12-08 Auspex Pharmaceutical, Inc. Benzoquinolone inhibitors of vmat2
EP2897615A4 (en) * 2012-09-18 2016-04-27 Auspex Pharmaceuticals Inc PHARMACOKINETIC FORMULATIONS OF DEUTERATED BENZOCHINOL INHIBITORS OF THE VESICLE MONOAMINE TRANSPORTER 2
WO2015120317A1 (en) * 2014-02-07 2015-08-13 Neurocrine Biosciences, Inc. Pharmaceutical compositions comprising an antipsychotic drug and a vmat2 inhibitor and uses thereof

Also Published As

Publication number Publication date
EP3139925B1 (en) 2021-12-01
PL3139925T3 (pl) 2022-03-21
US20170071932A1 (en) 2017-03-16
HUE066361T2 (hu) 2024-07-28
PT3139925T (pt) 2022-01-26
HUE057839T2 (hu) 2022-06-28
PL3936130T3 (pl) 2024-06-10
US20200101063A1 (en) 2020-04-02
KR20250029267A (ko) 2025-03-04
EP3139925A1 (en) 2017-03-15
EP4389227A2 (en) 2024-06-26
KR20200133003A (ko) 2020-11-25
IL248745B (en) 2022-07-01
SMT202400199T1 (it) 2024-07-09
MX387625B (es) 2025-03-18
LT3139925T (lt) 2022-01-25
SI3139925T1 (sl) 2022-04-29
MX2016014429A (es) 2017-04-06
KR20220140647A (ko) 2022-10-18
RU2753740C2 (ru) 2021-08-23
WO2015171802A1 (en) 2015-11-12
CN112741836A (zh) 2021-05-04
KR20160147044A (ko) 2016-12-21
IL248745A0 (en) 2017-01-31
JP2021191799A (ja) 2021-12-16
JP2019218407A (ja) 2019-12-26
US20210196702A1 (en) 2021-07-01
CY1125058T1 (el) 2023-06-09
RS62782B1 (sr) 2022-01-31
SMT202200193T1 (it) 2022-07-21
FI3936130T3 (fi) 2024-04-23
CA2947736C (en) 2023-04-18
LT3936130T (lt) 2024-04-25
JP2017514850A (ja) 2017-06-08
SI3936130T1 (sl) 2024-05-31
JP6635945B2 (ja) 2020-01-29
CN106456629A (zh) 2017-02-22
EP3936130A1 (en) 2022-01-12
CA2947736A1 (en) 2015-11-12
RU2016147523A (ru) 2018-06-08
HRP20240459T1 (hr) 2024-06-21
EP4389227A3 (en) 2024-09-04
ES2976207T3 (es) 2024-07-26
AU2015256012B2 (en) 2020-07-23
HRP20220025T1 (hr) 2022-04-01
DK3936130T3 (da) 2024-03-25
PT3936130T (pt) 2024-04-17
EP3936130B1 (en) 2024-02-14
KR20240011255A (ko) 2024-01-25
DK3139925T3 (da) 2021-12-20
JP2024153782A (ja) 2024-10-29
NZ725826A (en) 2023-05-26
AU2015256012A1 (en) 2016-11-24
ES2904526T3 (es) 2022-04-05
RS65359B1 (sr) 2024-04-30
RU2016147523A3 (enExample) 2018-12-28

Similar Documents

Publication Publication Date Title
CN112741835A (zh) 用于运动机能亢进性运动障碍的治疗的vmat2抑制剂
EP3606525B1 (en) Compositions for treating aging-associated impairments using ccr3-inhibitors
JP2017519827A (ja) ブスピロン代謝産物の使用
US11191758B2 (en) Use of selective serotonin 5-HT1A receptor agonists for treating side-effects of VMAT inhibitors
HK40111840A (en) Valbenazine dosage regimen for the treatment of hyperkinetic movement disorders
HK40067005A (en) Valbenazine dosage regimen for the treatment of hyperkinetic movement disorders
HK1235303A1 (en) Valbenazine dosage regimen for the treatment of hyperkinetic movement disorders
HK40067005B (en) Valbenazine dosage regimen for the treatment of hyperkinetic movement disorders
HK1235303B (en) Valbenazine dosage regimen for the treatment of hyperkinetic movement disorders
US20120172390A1 (en) Method of treating sleep disorders using the combination of eplivanserin and zolpidem
US20080070952A1 (en) Inhibition or Treatment of Dyskinesia

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination